An interventional study of Aveera in Obstructive Sleep Apnea, sponsored by Metamason. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by Metamason · Not applicable, Interventional, and Other
Feasibility study to assess the scan, fit and print process for the Aveera "Patient Matched" CPAP Mask
2,198 studies on the registry are indexed under Sleep Apnea, Obstructive; 469 are open to participants now.
This study's enrollment of 13 is below the median of 53 across 1,448 interventional studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →This is the only study on the registry with Metamason as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
Device: Aveera
Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
1) Measure time frame from scanning to mask fit and subjective patient feedback of mask fit
Assess the clinical utility of using a 3D scanning process, printing and fit assessment
Time frame: 2 weeks
Plan to share: No — there is no plan to share individual data
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.